PERTH, Australia – Drug safety advisories around the globe are often inconsistent, and Australia's Therapeutic Goods Administration (TGA) is one of the most inconsistent compared to its peers, according to a review of drug regulators in Australia, Canada, the U.K. and the U.S. over the last decade.
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
PERTH, Australia – Que Oncology Inc., a joint venture between Emory University and the University of Queensland, has kicked off its phase II trials in the U.S. and Australia for its lead therapy to treat hot flashes in breast cancer patients.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) has updated its requirements for risk management plans to be submitted with applications for new drugs and biologics.
PERTH, Australia – Singapore-headquartered Cerecin Inc. is gearing up for a series of phase II trials in Australia of its lead compound, tricaprilin, for Alzheimer's disease.
